Hims Stock Surges Following Deal with Novo Nordisk
Prior to March 9, 2026, Hims & Hers Health faced significant challenges regarding its position in the weight-loss medication market. The company had been embroiled in a lawsuit with Novo Nordisk, which accused Hims of infringing on a key US patent related to semaglutide, the active ingredient in Novo Nordisk’s popular obesity drug, Wegovy. Hims had previously declined to cease selling lower-cost compounded versions of this drug, which had led to tensions between the two companies.
However, a decisive moment occurred when Hims & Hers Health struck a deal with Novo Nordisk to sell its weight-loss medicine on Hims’ platform. This agreement not only resolves the ongoing legal dispute but also allows Hims to market a legitimate version of the medication, which had been a contentious point in their relationship.
The immediate impact of this development was notable. Hims & Hers shares surged by 53.1 percent in premarket trading, reaching a price of $24.1. This marked a significant rebound for the company, reflecting investor optimism about the new partnership. In contrast, Novo Nordisk’s stock rose by a modest 0.8 percent, indicating a more tempered response from the market.
The partnership comes after a previous agreement between the companies collapsed in June 2025, which had left Hims in a precarious position. The new deal not only ends the lawsuit aimed at stopping Hims from selling a copycat version of Wegovy but also allows the company to withdraw its plans to sell compounded versions of Novo Nordisk’s newly launched oral obesity therapy.
Experts suggest that this partnership could enhance Hims & Hers Health’s market presence significantly, as it aligns the company with a leading player in the obesity treatment sector. The resolution of the lawsuit and the establishment of a legitimate sales channel for weight-loss medication could bolster Hims’ credibility in the healthcare market.
As the situation unfolds, investors and analysts will be closely monitoring the performance of both companies in the coming weeks. The shift in Hims’ stock price reflects a broader confidence in the company’s future prospects, particularly in the competitive landscape of weight-loss treatments.
Details remain unconfirmed regarding the long-term implications of this partnership, but the immediate effects are clear: Hims & Hers Health has turned a corner, and the market is responding positively.
